Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zai Lab Approved to Launch Novel Antibiotic in China for Pneumonia

publication date: Dec 17, 2021

Shanghai Zai Lab was approved in China to launch Nuzyra® (omadacycline), a novel antibiotic available in oral and intravenous formulations, to treat community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Nuzyra was designed to overcome tetracycline resistance and improve treatment in several bacterial infections. In 2017, Zai acquired greater China rights to the antibiotic from Paratek Pharma of Boston. It made a $7.5 million upfront payment and is responsible for unspecified milestones plus royalties. More details....

Stock Symbols: (NSDQ: ZLAB; HK: 9688)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here